TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

TitleTMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
Publication TypeJournal Article
Year of Publication2007
AuthorsDemichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera J-M, Pawitan Y, Lee C, Adami H-O, Mucci LA, Kantoff PW, Andersson S-O, Chinnaiyan AM, Johansson J-E, Rubin MA
Date Published2007 Jul 5
KeywordsAged, Aged, 80 and over, Cohort Studies, Gene Fusion, Humans, In Situ Hybridization, Fluorescence, Male, Middle Aged, Oncogene Proteins, Fusion, Polymerase Chain Reaction, Prostatic Neoplasms

The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

Alternate JournalOncogene
PubMed ID17237811
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
R01AG21404 / AG / NIA NIH HHS / United States
UO1CA113913 / CA / NCI NIH HHS / United States